- The Supper
- Posts
- TrumpRx Program and Drug Price Cuts Announced
In partnership with
President Donald Trump unveiled a new initiative dubbed “TrumpRx,” aimed at slashing drug prices through a novel trade-based strategy. Under the program, pharmaceutical companies that agree to lower prices on key medications will receive tariff exemptions on imported raw materials. The first wave of agreements includes deals with Eli Lilly and Novo Nordisk to reduce the cost of GLP-1 drugs used for weight loss and diabetes management.
The best marketing ideas come from marketers who live it.
That’s what this newsletter delivers.
The Marketing Millennials is a look inside what’s working right now for other marketers. No theory. No fluff. Just real insights and ideas you can actually use—from marketers who’ve been there, done that, and are sharing the playbook.
Every newsletter is written by Daniel Murray, a marketer obsessed with what goes into great marketing. Expect fresh takes, hot topics, and the kind of stuff you’ll want to steal for your next campaign.
Because marketing shouldn’t feel like guesswork. And you shouldn’t have to dig for the good stuff.
The announcement was dramatic, with a Novo Nordisk executive collapsing on stage during the press conference. While the incident was later attributed to dehydration, it underscored the high-stakes nature of pharmaceutical reform. Trump emphasized that the program would “put patients first” and promised further deals in the coming months targeting cancer treatments and insulin.
Critics argue that the plan lacks transparency and could favor large pharmaceutical firms over smaller competitors. Others worry about the long-term impact on drug innovation. Still, early reactions from patient groups have been cautiously optimistic, especially given the skyrocketing demand for GLP-1 medications like Ozempic and Wegovy. If successful, TrumpRx could reshape how drug pricing is negotiated in the U.S.
Reply